Bausch Health Files 8-K: Other Events & Financials
Ticker: BHC · Form: 8-K · Filed: Dec 9, 2025 · CIK: 885590
Sentiment: neutral
Topics: 8-K, financial-reporting, corporate-events
Related Tickers: BHC
TL;DR
Bausch Health (BHC) filed an 8-K on Dec 9 for events on Dec 8 - check for updates.
AI Summary
Bausch Health Companies Inc. filed an 8-K on December 9, 2025, reporting an event that occurred on December 8, 2025. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits'. The company, formerly known as Valeant Pharmaceuticals International, Inc., is headquartered in Laval, Quebec, Canada.
Why It Matters
This filing indicates updates or significant events for Bausch Health Companies Inc., potentially impacting investors' understanding of the company's current status and financial reporting.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, indicating an event or financial statement disclosure, which is standard corporate reporting.
Key Players & Entities
- Bausch Health Companies Inc. (company) — Registrant
- Valeant Pharmaceuticals International, Inc. (company) — Former Company Name
- December 8, 2025 (date) — Date of earliest event reported
- December 9, 2025 (date) — Filing Date
FAQ
What specific 'Other Events' are being reported by Bausch Health Companies Inc. in this 8-K filing?
The provided text does not specify the details of the 'Other Events', only that this item is included in the filing.
What is the significance of the 'Financial Statements and Exhibits' being reported?
This indicates that the filing includes financial statements and supporting exhibits, which are crucial for investors to assess the company's financial health and performance.
When was Bausch Health Companies Inc. formerly known as Valeant Pharmaceuticals International, Inc.?
The filing states the date of the name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was September 28, 2010.
What is the principal executive office address for Bausch Health Companies Inc.?
The principal executive offices are located at 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8.
What is the SEC file number for Bausch Health Companies Inc.?
The SEC file number for Bausch Health Companies Inc. is 001-14956.
Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-12-08 19:30:25
Key Financial Figures
- $1.6 billion — Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00
Filing Documents
- bhc-20251208.htm (8-K) — 30KB
- bausch-earlyresultspressre.htm (EX-99.1) — 21KB
- image_0a.jpg (GRAPHIC) — 4KB
- 0000885590-25-000054.txt ( ) — 181KB
- bhc-20251208.xsd (EX-101.SCH) — 2KB
- bhc-20251208_lab.xml (EX-101.LAB) — 22KB
- bhc-20251208_pre.xml (EX-101.PRE) — 13KB
- bhc-20251208_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On December 8, 2025, Bausch Health Companies Inc. (the "Company") announced the early results, as of 5:00 p.m., New York City time, on December 8, 2025, of the previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 (the "Offers") to be issued by the Company's indirect wholly-owned subsidiary 1261229 B.C. Ltd., in each case, pursuant to the terms described in a confidential exchange offer memorandum dated November 24, 2025 (the " Exchange Offer Memorandum "). A copy of the Company's press release announcing the early results of the Offers is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or purchase, or the solicitation of tenders with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Offers are being made solely pursuant to the Exchange Offer Memorandum and only to such persons and in such jurisdictions as is permitted under applicable law. The New Notes will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The New Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Number Description 99.1* Press Release of Bausch Health Companies Inc., dated December 8, 2025, relating to the early results of exchange offers 101.SCH* XBRL Taxonomy Extension Schema Document 101.LAB* XBRL Taxonomy Extension Label Linkbase Document 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document 104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ____________________________________ * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 8, 2025 BAUSCH HEALTH COMPANIES INC. By: /s/ Jean-Jacques Charhon Jean-Jacques Charhon Executive Vice President, Chief Financial Officer (Principal Financial Officer)